Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)
Clinical trial NCT04961359 · COMPLETED
Trial details
- NCT number
- NCT04961359
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-03
- Primary completion
- 2021-12-12
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.